Understanding of the metabolic abnormalities induced by COMT inhibitor administration

2014 Fiscal Year Final Research Report

• Project/Area Number: 24590189
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Medical pharmacy
• Research Institution: Shiga University of Medical Science
• Principal Investigator: KIM Hyoh 滋賀医科大学, 医学部, 助教 (10612377)
• Co-Investigator(Kenkyū-buntansha): KANASAKI Keizo 金沢医科大学, 医学部, 講師 (60589919)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: COMT / インスリン抵抗性 / パーキンソン病

Outline of Final Research Achievements

COMT is an enzyme involved in the inactivation of catecholamines, a neurotransmitter of the sympathetic nervous system. Its inhibitors are clinically practical use as a therapeutic agent for Parkinson's disease in Japan.
In our animal and cell experiment, glucose tolerance deteriorates under a high-fat diet by the COMT failure proved by insulin secretion decrease. Improvement of glucose intolerance with COMT metabolites proved that by improving insulin resistance.
The result of the influence on the metabolism of COMT inhibitors which are used in Parkinson's disease patients was investigated in glucose tolerance test, there were not observed problems with obvious metabolic abnormalities within therapeutic dose. However it appeared to require further consideration.

Free Research Field

神経内科